{
 "生成时间": "2026-10-13 02:05",
 "口径": "全部为 curl 实测 HTTP 状态码（2026-10-12 深夜），不是推测",
 "竞品源": {
  "诺唯赞": {
   "官网": "https://bio.vazyme.com/",
   "状态": "200",
   "财报": "巨潮/上交所（688105）",
   "备注": "/product/<id> 有路径级 WAF，加 .html 或尾斜杠可绕过（已实测）"
  },
  "翌圣": {
   "官网": "https://www.yeasen.com/",
   "状态": "200",
   "财报": "待核（是否已上市需确认）"
  },
  "菲鹏": {
   "官网": "https://www.faponbiotech.com/",
   "状态": "200",
   "财报": "无（IPO 未完成）",
   "补充": "https://www.fapon.com/ 200"
  },
  "全式金": {
   "官网": "https://www.transgen.com/",
   "状态": "200",
   "财报": "无（未上市）",
   "补充": "分子诊断解决方案页含货号级产品与卖点"
  },
  "迈迪安": {
   "官网": "https://www.meridianbioscience.com/",
   "状态": "200",
   "财报": "待核（疑已私有化 → 无公开季报）"
  },
  "罗氏": {
   "IR": "https://www.roche.com/investors",
   "状态": "200",
   "财报": "半年报/年报（IR 页）",
   "备注": "RSS 路径 404，需用 IR 页；diagnostics.roche.com 404"
  },
  "宝生物(Takara)": {
   "官网国际": "https://www.takarabio.com/",
   "状态": "403（WAF）",
   "中文站": "https://www.takara.com.cn/ 200",
   "财报": "已退市（2026-06-12）→ 无季报",
   "备注": "情报可见度下降，改官网/展会/渠道侧跟踪"
  },
  "赛默飞": {
   "官网": "https://www.thermofisher.com/",
   "状态": "200",
   "企业新闻室": "https://corporate.thermofisher.com/ 200",
   "财报": "IR 站 403；SEC EDGAR 403（需换合规 UA 再试）"
  }
 },
 "官方披露平台": {
  "巨潮资讯": "200",
  "上交所": "200",
  "深交所": "200",
  "SEC EDGAR": "403（待解）"
 },
 "行业媒体": {
  "动脉网": "200",
  "生物谷": "200",
  "测序中国": "000（域名不通）",
  "医业观察": "000（域名不通）"
 },
 "招投标": {
  "中国政府采购网": "403（反爬）",
  "各省公共资源交易中心": "待逐个实测"
 },
 "关键结论": [
  "8 家里真正有公开财报的只有 3 家：诺唯赞（688105）、罗氏（IR 半年报/年报）、赛默飞（IR 被拦，需另找入口）；翌圣/菲鹏/全式金/迈迪安/宝生物 均无公开季报可抓。",
  "客户侧反而更有料：她 20 家客户里多家为 A 股上市（丽珠/复星/迪安/东方基因/新产业/科华/之江/艾德…），财报统一走巨潮，覆盖面比竞品侧更完整。",
  "宝生物国际站被 WAF 拦，改用中文站 takara.com.cn（200）。",
  "招投标类源普遍反爬（403），必须先试跑再承诺每日。"
 ]
}